All In Biotech

Free tool

FAERS Monitor: Datscan

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022454 or its brand name (Datscan, Ioflupane I-123). Reports on generic versions are filed under their own applications.

Reports

541

Serious

90

17% of reports

Hospitalization

17

Death reported

7

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • no adverse event263
  • radioisotope scan abnormal148
  • drug ineffective128
  • injection site pain59
  • drug interaction49
  • parkinsonism26
  • burning sensation24
  • false positive radioisotope investigation result16
  • dopamine transporter scintigraphy abnormal12
  • nausea12
  • product quality issue11
  • headache10
  • malaise10
  • dizziness9
  • pain9

Reports by year received

View as table
YearReports
20111
20131
20147
201516
201627
201774
201863
201955
202044
202137
202232
202337
202472
202550
202625

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,618 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
false positive radioisotope investigation resultSignal16103776.340762.0424,973
dopamine transporter scintigraphy abnormalSignal1222237.810996.1155,945
radioisotope scan abnormalSignal14810303.48776.41,197,358
parkinsonismSignal26103.971.42,543
no adverse eventSignal26356.551.814,390
burning sensationSignal2413.39.0262
drug interactionSignal4912.09.2487
injection site painSignal597.55.9329
drug ineffectiveSignal1283.83.2276
product quality issueSignal113.11.814
malaise100.90.50
dizziness90.70.41
headache100.60.32
nausea120.60.33
pain90.60.33

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.